ID   FOLH1_HUMAN             Reviewed;         750 AA.
AC   Q04609; A4UU12; A9CB79; B7Z312; B7Z343; D3DQS5; E9PDX8; O43748;
AC   Q16305; Q541A4; Q8TAY3; Q9NP15; Q9NYE2; Q9P1P8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   22-JUL-2015, entry version 171.
DE   RecName: Full=Glutamate carboxypeptidase 2;
DE            EC=3.4.17.21;
DE   AltName: Full=Cell growth-inhibiting gene 27 protein;
DE   AltName: Full=Folate hydrolase 1;
DE   AltName: Full=Folylpoly-gamma-glutamate carboxypeptidase;
DE            Short=FGCP;
DE   AltName: Full=Glutamate carboxypeptidase II;
DE            Short=GCPII;
DE   AltName: Full=Membrane glutamate carboxypeptidase;
DE            Short=mGCP;
DE   AltName: Full=N-acetylated-alpha-linked acidic dipeptidase I;
DE            Short=NAALADase I;
DE   AltName: Full=Prostate-specific membrane antigen;
DE            Short=PSM;
DE            Short=PSMA;
DE   AltName: Full=Pteroylpoly-gamma-glutamate carboxypeptidase;
GN   Name=FOLH1; Synonyms=FOLH, NAALAD1, PSM, PSMA; ORFNames=GIG27;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSMA-1), AND PARTIAL PROTEIN
RP   SEQUENCE.
RC   TISSUE=Prostatic carcinoma;
RX   PubMed=8417812;
RA   Israeli R.S., Powell C.T., Fair W.R., Heston W.D.W.;
RT   "Molecular cloning of a complementary DNA encoding a prostate-specific
RT   membrane antigen.";
RL   Cancer Res. 53:227-230(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSMA').
RC   TISSUE=Prostate;
RX   PubMed=7882349;
RA   Su S.L., Huang I.-P., Fair W.R., Powell C.T., Heston W.D.W.;
RT   "Alternatively spliced variants of prostate-specific membrane antigen
RT   RNA: ratio of expression as a potential measurement of progression.";
RL   Cancer Res. 55:1441-1443(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM PSMA-1), AND VARIANT
RP   HIS-75.
RX   PubMed=9838072; DOI=10.1016/S0167-4781(98)00200-0;
RA   O'Keefe D.S., Su S.L., Bacich D.J., Horiguchi Y., Luo Y., Powell C.T.,
RA   Zandvliet D., Russell P.J., Molloy P.L., Nowak N.J., Shows T.B.,
RA   Mullins C., Vonder Haar R.A., Fair W.R., Heston W.D.W.;
RT   "Mapping, genomic organization and promoter analysis of the human
RT   prostate-specific membrane antigen gene.";
RL   Biochim. Biophys. Acta 1443:113-127(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSMA-1).
RC   TISSUE=Brain;
RX   PubMed=9694964;
RA   Luthi-Carter R., Barczak A.K., Speno H., Coyle J.T.;
RT   "Molecular characterization of human brain N-acetylated alpha-linked
RT   acidic dipeptidase (NAALADase).";
RL   J. Pharmacol. Exp. Ther. 286:1020-1025(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSMA-1), AND CHARACTERIZATION.
RC   TISSUE=Prostate;
RX   PubMed=10085079; DOI=10.1074/jbc.274.13.8470;
RA   Pangalos M.N., Neefs J.-M., Somers M., Verhasselt P., Bekkers M.,
RA   van der Helm L., Fraiponts E., Ashton D., Gordon R.D.;
RT   "Isolation and expression of novel human glutamate carboxypeptidases
RT   with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl
RT   peptidase IV activity.";
RL   J. Biol. Chem. 274:8470-8483(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSMA-1), AND VARIANT TYR-475.
RC   TISSUE=Jejunum, and Small intestine;
RX   PubMed=11092759; DOI=10.1093/hmg/9.19.2837;
RA   Devlin A.M., Ling E.-H., Peerson J.M., Fernando S., Clarke R.,
RA   Smith A.D., Halsted C.H.;
RT   "Glutamate carboxypeptidase II: a polymorphism associated with lower
RT   levels of serum folate and hyperhomocysteinemia.";
RL   Hum. Mol. Genet. 9:2837-2844(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSMA-1).
RC   TISSUE=Prostatic carcinoma;
RA   Ye C.Z., Zhang F.L., Zhang Y.K., Chen C.Q.;
RT   "Cloning and sequencing of Chinese prostate-specific membrane
RT   antigen.";
RL   Mian Yi Xue Za Zhi 17:328-330(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSMA-9).
RX   PubMed=17929272; DOI=10.1002/pros.20664;
RA   Cao K.Y., Mao X.P., Wang D.H., Xu L., Yuan G.Q., Dai S.Q., Zheng B.J.,
RA   Qiu S.P.;
RT   "High expression of PSM-E correlated with tumor grade in prostate
RT   cancer: a new alternatively spliced variant of prostate-specific
RT   membrane antigen.";
RL   Prostate 67:1791-1800(2007).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Peace D.J., Zhang Y., Holt G., Ferrer K.T., Heller M., Sosman J.A.,
RA   Xue B.H.;
RT   "Identification of three novel splice variants of prostate-specific
RT   membrane antigen.";
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSMA-8).
RA   Kim J.W., Kim H.K., Shin S.M.;
RT   "Identification of a cell growth-inhibiting gene.";
RL   Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS PSMA-1; PSMA-7 AND
RP   10).
RC   TISSUE=Amygdala, Corpus callosum, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PSMA-8).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSMA-3), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Prostate;
RX   PubMed=9375657;
RA   Bzdega T., Turi T., Wroblewska B., She D., Chung H.S., Kim H.,
RA   Neale J.H.;
RT   "Molecular cloning of a peptidase against N-acetylaspartylglutamate
RT   from a rat hippocampal cDNA library.";
RL   J. Neurochem. 69:2270-2277(1997).
RN   [16]
RP   PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PSMA-4).
RA   Lupold S.E., Criley S.C., Coffey D.S.;
RT   "Alternative splicing of the prostate-specific membrane antigen.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   PROTEIN SEQUENCE OF 60-74, AND SUBCELLULAR LOCATION.
RC   TISSUE=Prostatic carcinoma;
RX   PubMed=9809977;
RA   Grauer L.S., Lawler K.D., Marignac J.L., Kumar A., Goel A.S.,
RA   Wolfert R.L.;
RT   "Identification, purification, and subcellular localization of
RT   prostate-specific membrane antigen PSM' protein in the LNCaP prostatic
RT   carcinoma cell line.";
RL   Cancer Res. 58:4787-4789(1998).
RN   [18]
RP   ALTERNATIVE SPLICING.
RA   Bzdega T., She D., Turi T., Wroblewska B., Neale J.H.;
RT   "Molecular cloning of alternatively spliced variants of the peptidase
RT   against N-acetylaspartylglutamate (NAAG) from human and rat nervous
RT   systems.";
RL   Abstr. - Soc. Neurosci. 24:579-579(1998).
RN   [19]
RP   CHARACTERIZATION.
RX   PubMed=9622670; DOI=10.1016/S0006-8993(98)00244-3;
RA   Luthi-Carter R., Barczak A.K., Speno H.D., Coyle J.T.;
RT   "Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by
RT   cloned human glutamate carboxypeptidase II.";
RL   Brain Res. 795:341-348(1998).
RN   [20]
RP   DOMAIN STRUCTURE.
RX   PubMed=9187245; DOI=10.1016/S0167-4838(97)00008-3;
RA   Rawlings N.D., Barrett A.J.;
RT   "Structure of membrane glutamate carboxypeptidase.";
RL   Biochim. Biophys. Acta 1339:247-252(1997).
RN   [21]
RP   MUTAGENESIS.
RX   PubMed=9882712;
RA   Speno H.S., Luthi-Carter R., Macias W.L., Valentine S.L.,
RA   Joshi A.R.T., Coyle J.T.;
RT   "Site-directed mutagenesis of predicted active site residues in
RT   glutamate carboxypeptidase II.";
RL   Mol. Pharmacol. 55:179-185(1999).
RN   [22]
RP   GLYCOSYLATION AT ASN-76; ASN-336; ASN-459; ASN-476 AND ASN-638.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [23]
RP   GLYCOSYLATION AT ASN-51; ASN-76; ASN-121; ASN-140; ASN-153; ASN-195;
RP   ASN-336; ASN-459; ASN-476 AND ASN-638, AND MUTAGENESIS OF ASN-51;
RP   ASN-76; ASN-121; ASN-140; ASN-153; ASN-195; ASN-336; ASN-459; ASN-476;
RP   ASN-638 AND THR-640.
RX   PubMed=15152093; DOI=10.1110/ps.04622104;
RA   Barinka C., Sacha P., Sklenar J., Man P., Bezouska K., Slusher B.S.,
RA   Konvalinka J.;
RT   "Identification of the N-glycosylation sites on glutamate
RT   carboxypeptidase II necessary for proteolytic activity.";
RL   Protein Sci. 13:1627-1635(2004).
RN   [24]
RP   TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=14716746; DOI=10.1002/pros.10319;
RA   O'Keefe D.S., Bacich D.J., Heston W.D.W.;
RT   "Comparative analysis of prostate-specific membrane antigen (PSMA)
RT   versus a prostate-specific membrane antigen-like gene.";
RL   Prostate 58:200-210(2004).
RN   [25]
RP   TISSUE SPECIFICITY.
RX   PubMed=16555021; DOI=10.1007/s00268-005-0544-5;
RA   Kinoshita Y., Kuratsukuri K., Landas S., Imaida K., Rovito P.M. Jr.,
RA   Wang C.Y., Haas G.P.;
RT   "Expression of prostate-specific membrane antigen in normal and
RT   malignant human tissues.";
RL   World J. Surg. 30:628-636(2006).
RN   [26]
RP   TISSUE SPECIFICITY.
RX   PubMed=17150306; DOI=10.1016/j.neuroscience.2006.10.022;
RA   Sacha P., Zamecnik J., Barinka C., Hlouchova K., Vicha A.,
RA   Mlcochova P., Hilgert I., Eckschlager T., Konvalinka J.;
RT   "Expression of glutamate carboxypeptidase II in human brain.";
RL   Neuroscience 144:1361-1372(2007).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 44-750 IN COMPLEXES WITH
RP   GLUTAMATE; INHIBITORS; CALCIUM AND ZINC IONS, COFACTOR, SUBUNIT, AND
RP   GLYCOSYLATION AT ASN-76; ASN-121; ASN-140; ASN-195; ASN-459; ASN-476
RP   AND ASN-638.
RX   PubMed=16467855; DOI=10.1038/sj.emboj.7600969;
RA   Mesters J.R., Barinka C., Li W., Tsukamoto T., Majer P., Slusher B.S.,
RA   Konvalinka J., Hilgenfeld R.;
RT   "Structure of glutamate carboxypeptidase II, a drug target in neuronal
RT   damage and prostate cancer.";
RL   EMBO J. 25:1375-1384(2006).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.19 ANGSTROMS) OF 44-750 IN COMPLEXES WITH THE
RP   INHIBITORS QUISQUALATE AND 2-PMPA; CALCIUM AND ZINC IONS, AND
RP   GLYCOSYLATION AT ASN-76; ASN-121; ASN-140; ASN-195; ASN-459; ASN-476
RP   AND ASN-638.
RX   PubMed=17372356; DOI=10.1107/S090744490700902X;
RA   Mesters J.R., Henning K., Hilgenfeld R.;
RT   "Human glutamate carboxypeptidase II inhibition: structures of GCPII
RT   in complex with two potent inhibitors, quisqualate and 2-PMPA.";
RL   Acta Crystallogr. D 63:508-513(2007).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.62 ANGSTROMS) OF 44-750 IN COMPLEXES WITH
RP   SUBSTRATE ANALOGS; CALCIUM AND ZINC IONS, ENZYME REGULATION, AND
RP   GLYCOSYLATION AT ASN-76; ASN-121; ASN-140 ASN-195; ASN-459; ASN-476
RP   AND ASN-638.
RX   PubMed=17567119; DOI=10.1021/jm070133w;
RA   Barinka C., Rovenska M., Mlcochova P., Hlouchova K., Plechanovova A.,
RA   Majer P., Tsukamoto T., Slusher B.S., Konvalinka J., Lubkowski J.;
RT   "Structural insight into the pharmacophore pocket of human glutamate
RT   carboxypeptidase II.";
RL   J. Med. Chem. 50:3267-3273(2007).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 44-750 IN COMPLEXES WITH
RP   UREA-BASED INHIBITORS; CALCIUM AND ZINC IONS, AND GLYCOSYLATION AT
RP   ASN-76; ASN-121; ASN-140; ASN-195; ASN-459; ASN-476 AND ASN-638.
RX   PubMed=19053759; DOI=10.1021/jm800765e;
RA   Barinka C., Byun Y., Dusich C.L., Banerjee S.R., Chen Y.,
RA   Castanares M., Kozikowski A.P., Mease R.C., Pomper M.G., Lubkowski J.;
RT   "Interactions between human glutamate carboxypeptidase II and urea-
RT   based inhibitors: structural characterization.";
RL   J. Med. Chem. 51:7737-7743(2008).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 44-750 IN COMPLEXES WITH
RP   SUBSTRATE ANALOGS; CALCIUM AND ZINC IONS, AND GLYCOSYLATION AT ASN-76;
RP   ASN-121; ASN-140; ASN-195; ASN-459; ASN-476 AND ASN-638.
RX   PubMed=18234225; DOI=10.1016/j.jmb.2007.12.066;
RA   Barinka C., Hlouchova K., Rovenska M., Majer P., Dauter M., Hin N.,
RA   Ko Y.-S., Tsukamoto T., Slusher B.S., Konvalinka J., Lubkowski J.;
RT   "Structural basis of interactions between human glutamate
RT   carboxypeptidase II and its substrate analogs.";
RL   J. Mol. Biol. 376:1438-1450(2008).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 44-750 IN COMPLEX WITH
RP   SUBSTRATE; CALCIUM AND ZINC IONS, GLYCOSYLATION AT ASN-76; ASN-121;
RP   ASN-140; ASN-195; ASN-459; ASN-476 AND ASN-638, AND MUTAGENESIS OF
RP   GLU-424.
RX   PubMed=19301871; DOI=10.1021/bi900220s;
RA   Klusak V., Barinka C., Plechanovova A., Mlcochova P., Konvalinka J.,
RA   Rulisek L., Lubkowski J.;
RT   "Reaction mechanism of glutamate carboxypeptidase II revealed by
RT   mutagenesis, X-ray crystallography, and computational methods.";
RL   Biochemistry 48:4126-4138(2009).
RN   [33]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-23.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Has both folate hydrolase and N-acetylated-alpha-linked-
CC       acidic dipeptidase (NAALADase) activity. Has a preference for tri-
CC       alpha-glutamate peptides. In the intestine, required for the
CC       uptake of folate. In the brain, modulates excitatory
CC       neurotransmission through the hydrolysis of the neuropeptide, N-
CC       aceylaspartylglutamate (NAAG), thereby releasing glutamate.
CC       Isoform PSM-4 and isoform PSM-5 would appear to be physiologically
CC       irrelevant. Involved in prostate tumor progression.
CC   -!- FUNCTION: Also exhibits a dipeptidyl-peptidase IV type activity.
CC       In vitro, cleaves Gly-Pro-AMC.
CC   -!- CATALYTIC ACTIVITY: Release of an unsubstituted, C-terminal
CC       glutamyl residue, typically from Ac-Asp-Glu or folylpoly-gamma-
CC       glutamates.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:16467855};
CC       Note=Binds 2 Zn(2+) ions per subunit. Required for NAALADase
CC       activity. {ECO:0000269|PubMed:16467855};
CC   -!- ENZYME REGULATION: The NAALADase activity is inhibited by beta-
CC       NAAG, quisqualic acid, 2-(phosphonomethyl) pentanedioic acid
CC       (PMPA) and EDTA. Activated by cobalt.
CC       {ECO:0000269|PubMed:17567119}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Stable at pH greater than 6.5.;
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:16467855,
CC       ECO:0000269|PubMed:19301871}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:9809977};
CC       Single-pass type II membrane protein {ECO:0000269|PubMed:9809977}.
CC   -!- SUBCELLULAR LOCATION: Isoform PSMA': Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=8;
CC       Name=PSMA-1;
CC         IsoId=Q04609-1; Sequence=Displayed;
CC         Note=No experimental confirmation available.;
CC       Name=PSMA-3;
CC         IsoId=Q04609-3; Sequence=VSP_040242, VSP_040245;
CC         Note=No experimental confirmation available. Incomplete
CC         sequence.;
CC       Name=PSMA-4;
CC         IsoId=Q04609-4; Sequence=VSP_040241, VSP_040243, VSP_040244;
CC         Note=No experimental confirmation available. Incomplete
CC         sequence.;
CC       Name=PSMA';
CC         IsoId=Q04609-6; Sequence=VSP_005336;
CC       Name=PSMA-7;
CC         IsoId=Q04609-7; Sequence=VSP_038058;
CC       Name=PSMA-8;
CC         IsoId=Q04609-8; Sequence=VSP_038059;
CC       Name=PSMA-9; Synonyms=PSM-E;
CC         IsoId=Q04609-9; Sequence=VSP_038058, VSP_038059;
CC       Name=10;
CC         IsoId=Q04609-10; Sequence=VSP_044287;
CC   -!- TISSUE SPECIFICITY: Highly expressed in prostate epithelium.
CC       Detected in urinary bladder, kidney, testis, ovary, fallopian
CC       tube, breast, adrenal gland, liver, esophagus, stomach, small
CC       intestine, colon and brain (at protein level). Detected in the
CC       small intestine, brain, kidney, liver, spleen, colon, trachea,
CC       spinal cord and the capillary endothelium of a variety of tumors.
CC       Expressed specifically in jejunum brush border membranes. In the
CC       brain, highly expressed in the ventral striatum and brain stem.
CC       Also expressed in fetal liver and kidney. Isoform PSMA' is the
CC       most abundant form in normal prostate. Isoform PSMA-1 is the most
CC       abundant form in primary prostate tumors. Isoform PSMA-2 is also
CC       found in normal prostate as well as in brain and liver. Isoform
CC       PSMA-9 is specifically expressed in prostate cancer.
CC       {ECO:0000269|PubMed:14716746, ECO:0000269|PubMed:16555021,
CC       ECO:0000269|PubMed:17150306, ECO:0000269|PubMed:9375657}.
CC   -!- INDUCTION: In the prostate, up-regulated in response to androgen
CC       deprivation.
CC   -!- DOMAIN: The NAALADase activity is found in the central region, the
CC       dipeptidyl peptidase IV type activity in the C-terminal.
CC       {ECO:0000269|PubMed:9187245}.
CC   -!- PTM: The first two amino acids at the N-terminus of isoform PSMA'
CC       appear to be cleaved by limited proteolysis.
CC   -!- PTM: The N-terminus is blocked.
CC   -!- POLYMORPHISM: Genetic variation in FOLH1 may be associated with
CC       low folate levels and consequent hyperhomocysteinemia. This
CC       condition can result in increased risk of cardiovascular disease,
CC       neural tube defects, and cognitive deficits.
CC   -!- MISCELLANEOUS: PSMA is used as a diagnostic and prognostic
CC       indicator of prostate cancer, and as a possible marker for various
CC       neurological disorders such as schizophrenia, Alzheimer disease
CC       and Huntington disease.
CC   -!- SIMILARITY: Belongs to the peptidase M28 family. M28B subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF31167.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M99487; AAA60209.1; -; mRNA.
DR   EMBL; S76978; AAB33750.2; -; mRNA.
DR   EMBL; AF007544; AAC83972.1; -; Genomic_DNA.
DR   EMBL; AF176574; AAD51121.1; -; mRNA.
DR   EMBL; EF488811; ABO93402.2; -; mRNA.
DR   EMBL; AY101595; AAM34479.1; -; mRNA.
DR   EMBL; AF107214; AAF31167.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; DQ088979; AAZ66619.1; -; mRNA.
DR   EMBL; AK312366; BAG35284.1; -; mRNA.
DR   EMBL; AK295368; BAH12048.1; -; mRNA.
DR   EMBL; AK295470; BAH12079.1; -; mRNA.
DR   EMBL; AC110742; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118273; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW67858.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW67861.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW67857.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW67859.1; -; Genomic_DNA.
DR   EMBL; BC025672; AAH25672.1; -; mRNA.
DR   EMBL; AF254358; AAF71358.1; -; mRNA.
DR   EMBL; AF254357; AAF71357.1; -; mRNA.
DR   CCDS; CCDS31493.1; -. [Q04609-8]
DR   CCDS; CCDS53626.1; -. [Q04609-10]
DR   CCDS; CCDS53627.1; -. [Q04609-9]
DR   CCDS; CCDS53628.1; -. [Q04609-7]
DR   CCDS; CCDS7946.1; -. [Q04609-1]
DR   PIR; A56881; A56881.
DR   RefSeq; NP_001014986.1; NM_001014986.1. [Q04609-8]
DR   RefSeq; NP_001180400.1; NM_001193471.1. [Q04609-7]
DR   RefSeq; NP_001180401.1; NM_001193472.1. [Q04609-9]
DR   RefSeq; NP_001180402.1; NM_001193473.1. [Q04609-10]
DR   RefSeq; NP_004467.1; NM_004476.1. [Q04609-1]
DR   UniGene; Hs.654487; -.
DR   PDB; 1Z8L; X-ray; 3.50 A; A/B/C/D=56-750.
DR   PDB; 2C6C; X-ray; 2.00 A; A=44-750.
DR   PDB; 2C6G; X-ray; 2.20 A; A=44-750.
DR   PDB; 2C6P; X-ray; 2.39 A; A=44-750.
DR   PDB; 2CIJ; X-ray; 2.40 A; A=44-750.
DR   PDB; 2JBJ; X-ray; 2.19 A; A=44-750.
DR   PDB; 2JBK; X-ray; 2.99 A; A=44-750.
DR   PDB; 2OOT; X-ray; 1.64 A; A=44-750.
DR   PDB; 2OR4; X-ray; 1.62 A; A=44-750.
DR   PDB; 2PVV; X-ray; 2.11 A; A=44-750.
DR   PDB; 2PVW; X-ray; 1.71 A; A=44-750.
DR   PDB; 2XEF; X-ray; 1.59 A; A=44-750.
DR   PDB; 2XEG; X-ray; 1.59 A; A=44-750.
DR   PDB; 2XEI; X-ray; 1.69 A; A=44-750.
DR   PDB; 2XEJ; X-ray; 1.78 A; A=44-750.
DR   PDB; 3BHX; X-ray; 1.60 A; A=44-750.
DR   PDB; 3BI0; X-ray; 1.67 A; A=44-750.
DR   PDB; 3BI1; X-ray; 1.50 A; A=44-750.
DR   PDB; 3BXM; X-ray; 1.71 A; A=44-750.
DR   PDB; 3D7D; X-ray; 1.69 A; A=44-750.
DR   PDB; 3D7F; X-ray; 1.54 A; A=44-750.
DR   PDB; 3D7G; X-ray; 1.75 A; A=44-750.
DR   PDB; 3D7H; X-ray; 1.55 A; A=44-750.
DR   PDB; 3IWW; X-ray; 2.30 A; A=44-750.
DR   PDB; 3RBU; X-ray; 1.60 A; A=44-750.
DR   PDB; 3SJE; X-ray; 1.70 A; A=44-750.
DR   PDB; 3SJF; X-ray; 1.65 A; A=44-750.
DR   PDB; 3SJG; X-ray; 1.65 A; A=44-750.
DR   PDB; 3SJX; X-ray; 1.66 A; A=44-750.
DR   PDB; 4JYW; X-ray; 1.73 A; A=44-750.
DR   PDB; 4JZ0; X-ray; 1.83 A; A=44-750.
DR   PDB; 4LQG; X-ray; 1.77 A; A=44-750.
DR   PDB; 4MCP; X-ray; 1.65 A; A=44-750.
DR   PDB; 4MCQ; X-ray; 2.00 A; A=44-750.
DR   PDB; 4MCR; X-ray; 1.65 A; A=44-750.
DR   PDB; 4MCS; X-ray; 1.83 A; A=44-750.
DR   PDB; 4NGM; X-ray; 1.84 A; A=44-750.
DR   PDB; 4NGN; X-ray; 1.64 A; A=44-750.
DR   PDB; 4NGP; X-ray; 1.63 A; A=44-750.
DR   PDB; 4NGQ; X-ray; 2.08 A; A=44-750.
DR   PDB; 4NGR; X-ray; 1.90 A; A=44-750.
DR   PDB; 4NGS; X-ray; 1.68 A; A=44-750.
DR   PDB; 4NGT; X-ray; 2.31 A; A=44-750.
DR   PDB; 4OC0; X-ray; 1.85 A; A=44-750.
DR   PDB; 4OC1; X-ray; 1.75 A; A=44-750.
DR   PDB; 4OC2; X-ray; 1.65 A; A=44-750.
DR   PDB; 4OC3; X-ray; 1.79 A; A=44-750.
DR   PDB; 4OC4; X-ray; 1.66 A; A=44-750.
DR   PDB; 4OC5; X-ray; 1.70 A; A=44-750.
DR   PDB; 4OME; X-ray; 1.79 A; A=44-750.
DR   PDB; 4P44; X-ray; 1.75 A; A=44-750.
DR   PDB; 4P45; X-ray; 1.87 A; A=44-750.
DR   PDB; 4P4B; X-ray; 1.93 A; A=44-750.
DR   PDB; 4P4D; X-ray; 1.65 A; A=44-750.
DR   PDB; 4P4E; X-ray; 1.67 A; A=44-750.
DR   PDB; 4P4F; X-ray; 1.86 A; A=44-750.
DR   PDB; 4P4I; X-ray; 1.87 A; A=44-750.
DR   PDB; 4P4J; X-ray; 1.66 A; A=44-750.
DR   PDBsum; 1Z8L; -.
DR   PDBsum; 2C6C; -.
DR   PDBsum; 2C6G; -.
DR   PDBsum; 2C6P; -.
DR   PDBsum; 2CIJ; -.
DR   PDBsum; 2JBJ; -.
DR   PDBsum; 2JBK; -.
DR   PDBsum; 2OOT; -.
DR   PDBsum; 2OR4; -.
DR   PDBsum; 2PVV; -.
DR   PDBsum; 2PVW; -.
DR   PDBsum; 2XEF; -.
DR   PDBsum; 2XEG; -.
DR   PDBsum; 2XEI; -.
DR   PDBsum; 2XEJ; -.
DR   PDBsum; 3BHX; -.
DR   PDBsum; 3BI0; -.
DR   PDBsum; 3BI1; -.
DR   PDBsum; 3BXM; -.
DR   PDBsum; 3D7D; -.
DR   PDBsum; 3D7F; -.
DR   PDBsum; 3D7G; -.
DR   PDBsum; 3D7H; -.
DR   PDBsum; 3IWW; -.
DR   PDBsum; 3RBU; -.
DR   PDBsum; 3SJE; -.
DR   PDBsum; 3SJF; -.
DR   PDBsum; 3SJG; -.
DR   PDBsum; 3SJX; -.
DR   PDBsum; 4JYW; -.
DR   PDBsum; 4JZ0; -.
DR   PDBsum; 4LQG; -.
DR   PDBsum; 4MCP; -.
DR   PDBsum; 4MCQ; -.
DR   PDBsum; 4MCR; -.
DR   PDBsum; 4MCS; -.
DR   PDBsum; 4NGM; -.
DR   PDBsum; 4NGN; -.
DR   PDBsum; 4NGP; -.
DR   PDBsum; 4NGQ; -.
DR   PDBsum; 4NGR; -.
DR   PDBsum; 4NGS; -.
DR   PDBsum; 4NGT; -.
DR   PDBsum; 4OC0; -.
DR   PDBsum; 4OC1; -.
DR   PDBsum; 4OC2; -.
DR   PDBsum; 4OC3; -.
DR   PDBsum; 4OC4; -.
DR   PDBsum; 4OC5; -.
DR   PDBsum; 4OME; -.
DR   PDBsum; 4P44; -.
DR   PDBsum; 4P45; -.
DR   PDBsum; 4P4B; -.
DR   PDBsum; 4P4D; -.
DR   PDBsum; 4P4E; -.
DR   PDBsum; 4P4F; -.
DR   PDBsum; 4P4I; -.
DR   PDBsum; 4P4J; -.
DR   ProteinModelPortal; Q04609; -.
DR   SMR; Q04609; 55-750.
DR   BioGrid; 108630; 4.
DR   IntAct; Q04609; 4.
DR   MINT; MINT-3025010; -.
DR   STRING; 9606.ENSP00000256999; -.
DR   BindingDB; Q04609; -.
DR   ChEMBL; CHEMBL1892; -.
DR   DrugBank; DB00089; Capromab.
DR   GuidetoPHARMACOLOGY; 1606; -.
DR   MEROPS; M28.010; -.
DR   PhosphoSite; Q04609; -.
DR   BioMuta; FOLH1; -.
DR   DMDM; 548615; -.
DR   MaxQB; Q04609; -.
DR   PaxDb; Q04609; -.
DR   PRIDE; Q04609; -.
DR   DNASU; 2346; -.
DR   Ensembl; ENST00000256999; ENSP00000256999; ENSG00000086205.
DR   Ensembl; ENST00000340334; ENSP00000344131; ENSG00000086205. [Q04609-7]
DR   Ensembl; ENST00000343844; ENSP00000344086; ENSG00000086205. [Q04609-10]
DR   Ensembl; ENST00000356696; ENSP00000349129; ENSG00000086205. [Q04609-8]
DR   Ensembl; ENST00000533034; ENSP00000431463; ENSG00000086205. [Q04609-9]
DR   GeneID; 2346; -.
DR   KEGG; hsa:2346; -.
DR   UCSC; uc001ngx.3; human. [Q04609-3]
DR   UCSC; uc001ngy.3; human. [Q04609-1]
DR   UCSC; uc001ngz.3; human. [Q04609-8]
DR   UCSC; uc009yly.3; human. [Q04609-7]
DR   UCSC; uc009ylz.3; human. [Q04609-9]
DR   CTD; 2346; -.
DR   GeneCards; GC11M049168; -.
DR   H-InvDB; HIX0129475; -.
DR   HGNC; HGNC:3788; FOLH1.
DR   HPA; CAB001451; -.
DR   HPA; HPA010593; -.
DR   MIM; 600934; gene.
DR   neXtProt; NX_Q04609; -.
DR   PharmGKB; PA28205; -.
DR   eggNOG; NOG74799; -.
DR   GeneTree; ENSGT00550000074421; -.
DR   HOGENOM; HOG000211921; -.
DR   HOVERGEN; HBG051639; -.
DR   InParanoid; Q04609; -.
DR   KO; K14592; -.
DR   OMA; HYATHAN; -.
DR   OrthoDB; EOG7QK0BC; -.
DR   PhylomeDB; Q04609; -.
DR   TreeFam; TF312981; -.
DR   BRENDA; 3.4.17.21; 2681.
DR   EvolutionaryTrace; Q04609; -.
DR   GeneWiki; Glutamate_carboxypeptidase_II; -.
DR   GenomeRNAi; 2346; -.
DR   NextBio; 9513; -.
DR   PRO; PR:Q04609; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; Q04609; -.
DR   CleanEx; HS_FOLH1; -.
DR   ExpressionAtlas; Q04609; baseline.
DR   Genevisible; Q04609; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0004180; F:carboxypeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0016805; F:dipeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008237; F:metallopeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0008233; F:peptidase activity; NAS:UniProtKB.
DR   GO; GO:0006760; P:folic acid-containing compound metabolic process; IEA:Ensembl.
DR   GO; GO:0006508; P:proteolysis; NAS:UniProtKB.
DR   Gene3D; 1.20.930.40; -; 1.
DR   InterPro; IPR007484; Peptidase_M28.
DR   InterPro; IPR003137; Protease-assoc_domain.
DR   InterPro; IPR007365; TFR-like_dimer_dom.
DR   Pfam; PF02225; PA; 1.
DR   Pfam; PF04389; Peptidase_M28; 1.
DR   Pfam; PF04253; TFR_dimer; 1.
DR   SUPFAM; SSF47672; SSF47672; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Carboxypeptidase;
KW   Cell membrane; Complete proteome; Cytoplasm; Dipeptidase;
KW   Direct protein sequencing; Glycoprotein; Hydrolase; Membrane;
KW   Metal-binding; Metalloprotease; Multifunctional enzyme; Polymorphism;
KW   Protease; Reference proteome; Signal-anchor; Transmembrane;
KW   Transmembrane helix; Zinc.
FT   CHAIN         1    750       Glutamate carboxypeptidase 2.
FT                                /FTId=PRO_0000174117.
FT   TOPO_DOM      1     19       Cytoplasmic. {ECO:0000305}.
FT   TRANSMEM     20     43       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000305}.
FT   TOPO_DOM     44    750       Extracellular. {ECO:0000305}.
FT   REGION      274    587       NAALADase.
FT   REGION      534    536       Substrate binding.
FT   REGION      699    700       Substrate binding.
FT   COMPBIAS    146    149       Poly-Pro.
FT   ACT_SITE    424    424       For NAALADase activity.
FT   ACT_SITE    628    628       Charge relay system. {ECO:0000255}.
FT   ACT_SITE    666    666       Charge relay system. {ECO:0000255}.
FT   ACT_SITE    689    689       Charge relay system. {ECO:0000255}.
FT   METAL       269    269       Calcium. {ECO:0000269|PubMed:19301871}.
FT   METAL       272    272       Calcium; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:19301871}.
FT   METAL       377    377       Zinc 1.
FT   METAL       387    387       Zinc 1.
FT   METAL       387    387       Zinc 2.
FT   METAL       425    425       Zinc 2.
FT   METAL       433    433       Calcium. {ECO:0000269|PubMed:19301871}.
FT   METAL       436    436       Calcium. {ECO:0000269|PubMed:19301871}.
FT   METAL       453    453       Zinc 1.
FT   METAL       553    553       Zinc 2.
FT   BINDING     210    210       Substrate. {ECO:0000269|PubMed:19301871}.
FT   BINDING     257    257       Substrate. {ECO:0000269|PubMed:19301871}.
FT   BINDING     519    519       Substrate. {ECO:0000269|PubMed:19301871}.
FT   BINDING     552    552       Substrate. {ECO:0000269|PubMed:19301871}.
FT   CARBOHYD     51     51       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15152093}.
FT   CARBOHYD     76     76       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:15152093,
FT                                ECO:0000269|PubMed:16467855,
FT                                ECO:0000269|PubMed:17372356,
FT                                ECO:0000269|PubMed:17567119,
FT                                ECO:0000269|PubMed:18234225,
FT                                ECO:0000269|PubMed:19053759,
FT                                ECO:0000269|PubMed:19301871}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15152093,
FT                                ECO:0000269|PubMed:16467855,
FT                                ECO:0000269|PubMed:17372356,
FT                                ECO:0000269|PubMed:17567119,
FT                                ECO:0000269|PubMed:18234225,
FT                                ECO:0000269|PubMed:19053759,
FT                                ECO:0000269|PubMed:19301871}.
FT   CARBOHYD    140    140       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15152093,
FT                                ECO:0000269|PubMed:16467855,
FT                                ECO:0000269|PubMed:17372356,
FT                                ECO:0000269|PubMed:17567119,
FT                                ECO:0000269|PubMed:18234225,
FT                                ECO:0000269|PubMed:19053759,
FT                                ECO:0000269|PubMed:19301871}.
FT   CARBOHYD    153    153       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15152093}.
FT   CARBOHYD    195    195       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:15152093,
FT                                ECO:0000269|PubMed:16467855,
FT                                ECO:0000269|PubMed:17372356,
FT                                ECO:0000269|PubMed:17567119,
FT                                ECO:0000269|PubMed:18234225,
FT                                ECO:0000269|PubMed:19053759,
FT                                ECO:0000269|PubMed:19301871}.
FT   CARBOHYD    336    336       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:15152093}.
FT   CARBOHYD    459    459       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:15152093,
FT                                ECO:0000269|PubMed:16467855,
FT                                ECO:0000269|PubMed:17372356,
FT                                ECO:0000269|PubMed:17567119,
FT                                ECO:0000269|PubMed:18234225,
FT                                ECO:0000269|PubMed:19053759,
FT                                ECO:0000269|PubMed:19301871}.
FT   CARBOHYD    476    476       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:15152093,
FT                                ECO:0000269|PubMed:16467855,
FT                                ECO:0000269|PubMed:17372356,
FT                                ECO:0000269|PubMed:17567119,
FT                                ECO:0000269|PubMed:18234225,
FT                                ECO:0000269|PubMed:19053759,
FT                                ECO:0000269|PubMed:19301871}.
FT   CARBOHYD    638    638       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:15152093,
FT                                ECO:0000269|PubMed:16467855,
FT                                ECO:0000269|PubMed:17372356,
FT                                ECO:0000269|PubMed:17567119,
FT                                ECO:0000269|PubMed:18234225,
FT                                ECO:0000269|PubMed:19053759,
FT                                ECO:0000269|PubMed:19301871}.
FT   VAR_SEQ       1    585       Missing (in isoform PSMA-3).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_040242.
FT   VAR_SEQ       1    308       Missing (in isoform 10).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044287.
FT   VAR_SEQ       1    159       Missing (in isoform PSMA-4).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_040241.
FT   VAR_SEQ       1     57       Missing (in isoform PSMA').
FT                                {ECO:0000303|PubMed:7882349}.
FT                                /FTId=VSP_005336.
FT   VAR_SEQ       1     39       MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLF
FT                                -> MTAGSSYPLFLAAYACTGCLAERL (in isoform
FT                                PSMA-7 and isoform PSMA-9).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:17929272}.
FT                                /FTId=VSP_038058.
FT   VAR_SEQ     214    243       VKNAQLAGAKGVILYSDPADYFAPGVKSYP -> NMLIGVE
FT                                LQRLLVFQVFLFIQLDTMMHRSS (in isoform PSMA-
FT                                4). {ECO:0000305}.
FT                                /FTId=VSP_040243.
FT   VAR_SEQ     244    750       Missing (in isoform PSMA-4).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_040244.
FT   VAR_SEQ     657    750       NPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSH
FT                                NKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFT
FT                                VQAAAETLSEVA -> MSSMLQAATTSMQGSHSQEFMMLCL
FT                                ILKAKWTLPRPGEK (in isoform PSMA-3).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_040245.
FT   VAR_SEQ     657    688       NPIVLRMMNDQLMFLERAFIDPLGLPDRPFYR -> K (in
FT                                isoform PSMA-8 and isoform PSMA-9).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17929272,
FT                                ECO:0000303|Ref.10}.
FT                                /FTId=VSP_038059.
FT   VARIANT      23     23       A -> T (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036398.
FT   VARIANT      75     75       Y -> H (in dbSNP:rs202676).
FT                                {ECO:0000269|PubMed:9838072}.
FT                                /FTId=VAR_024592.
FT   VARIANT     475    475       H -> Y (can be associated with lower
FT                                folate and higher homocysteine levels;
FT                                dbSNP:rs61886492).
FT                                {ECO:0000269|PubMed:11092759}.
FT                                /FTId=VAR_012736.
FT   VARIANT     627    627       V -> L (in dbSNP:rs2988342).
FT                                /FTId=VAR_028882.
FT   MUTAGEN      51     51       N->A: Loss of glycosylation. Reduces
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:15152093}.
FT   MUTAGEN      76     76       N->A: Loss of glycosylation. Reduces
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:15152093}.
FT   MUTAGEN     121    121       N->A: Loss of glycosylation. Severely
FT                                reduced enzyme activity.
FT                                {ECO:0000269|PubMed:15152093}.
FT   MUTAGEN     140    140       N->A: Loss of glycosylation. Severely
FT                                reduced enzyme activity.
FT                                {ECO:0000269|PubMed:15152093}.
FT   MUTAGEN     153    153       N->A: Loss of glycosylation. Severely
FT                                reduced enzyme activity.
FT                                {ECO:0000269|PubMed:15152093}.
FT   MUTAGEN     195    195       N->A: Loss of glycosylation. Severely
FT                                reduced enzyme activity.
FT                                {ECO:0000269|PubMed:15152093}.
FT   MUTAGEN     336    336       N->A: Loss of glycosylation. Reduces
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:15152093}.
FT   MUTAGEN     377    377       H->A,G,Q: Complete loss of activity.
FT                                {ECO:0000269|PubMed:9882712}.
FT   MUTAGEN     379    379       D->E,N: Complete loss of activity.
FT                                {ECO:0000269|PubMed:9882712}.
FT   MUTAGEN     387    387       D->E,L: Complete loss of activity.
FT                                {ECO:0000269|PubMed:9882712}.
FT   MUTAGEN     387    387       D->N: No effect on enzyme activity.
FT                                {ECO:0000269|PubMed:9882712}.
FT   MUTAGEN     388    388       P->A: No effect on enzyme activity.
FT                                {ECO:0000269|PubMed:9882712}.
FT   MUTAGEN     424    424       E->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:19301871}.
FT   MUTAGEN     424    424       E->D: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:19301871}.
FT   MUTAGEN     424    424       E->Q: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:19301871}.
FT   MUTAGEN     425    425       E->Q,D: Complete loss of activity.
FT                                {ECO:0000269|PubMed:9882712}.
FT   MUTAGEN     453    453       D->N,L: Complete loss of activity.
FT                                {ECO:0000269|PubMed:9882712}.
FT   MUTAGEN     453    453       D->Q: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:9882712}.
FT   MUTAGEN     454    454       S->A: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:9882712}.
FT   MUTAGEN     459    459       N->A: Loss of glycosylation. Reduces
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:15152093}.
FT   MUTAGEN     476    476       N->A: Loss of glycosylation. Reduces
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:15152093}.
FT   MUTAGEN     638    638       N->A: Loss of glycosylation. Abolishes
FT                                enzyme activity.
FT                                {ECO:0000269|PubMed:15152093}.
FT   MUTAGEN     640    640       T->A: Abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:15152093}.
FT   CONFLICT    194    194       I -> V (in Ref. 9; AAZ66619).
FT                                {ECO:0000305}.
FT   CONFLICT    354    354       R -> K (in Ref. 1; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    398    398       I -> N (in Ref. 8; ABO93402).
FT                                {ECO:0000305}.
FT   HELIX        58     64       {ECO:0000244|PDB:3BI1}.
FT   HELIX        67     77       {ECO:0000244|PDB:3BI1}.
FT   STRAND       78     80       {ECO:0000244|PDB:3BI1}.
FT   HELIX        87    103       {ECO:0000244|PDB:3BI1}.
FT   STRAND      106    119       {ECO:0000244|PDB:3BI1}.
FT   STRAND      122    124       {ECO:0000244|PDB:2C6G}.
FT   STRAND      127    131       {ECO:0000244|PDB:3BI1}.
FT   STRAND      137    140       {ECO:0000244|PDB:3BI1}.
FT   TURN        149    151       {ECO:0000244|PDB:3D7H}.
FT   HELIX       154    156       {ECO:0000244|PDB:3IWW}.
FT   STRAND      174    176       {ECO:0000244|PDB:3BI1}.
FT   HELIX       182    190       {ECO:0000244|PDB:3BI1}.
FT   STRAND      200    204       {ECO:0000244|PDB:3BI1}.
FT   HELIX       210    219       {ECO:0000244|PDB:3BI1}.
FT   STRAND      223    228       {ECO:0000244|PDB:3BI1}.
FT   HELIX       231    234       {ECO:0000244|PDB:3BI1}.
FT   STRAND      244    247       {ECO:0000244|PDB:3BI1}.
FT   STRAND      269    272       {ECO:0000244|PDB:1Z8L}.
FT   HELIX       283    285       {ECO:0000244|PDB:3BI1}.
FT   STRAND      294    297       {ECO:0000244|PDB:3BI1}.
FT   HELIX       299    306       {ECO:0000244|PDB:3BI1}.
FT   HELIX       317    319       {ECO:0000244|PDB:3BI1}.
FT   STRAND      322    325       {ECO:0000244|PDB:3BI1}.
FT   STRAND      330    333       {ECO:0000244|PDB:3BI1}.
FT   HELIX       335    337       {ECO:0000244|PDB:3BI1}.
FT   STRAND      341    346       {ECO:0000244|PDB:3BI1}.
FT   STRAND      349    362       {ECO:0000244|PDB:3BI1}.
FT   STRAND      365    377       {ECO:0000244|PDB:3BI1}.
FT   STRAND      381    383       {ECO:0000244|PDB:3D7F}.
FT   TURN        385    388       {ECO:0000244|PDB:3BI1}.
FT   HELIX       389    407       {ECO:0000244|PDB:3BI1}.
FT   STRAND      413    423       {ECO:0000244|PDB:3BI1}.
FT   HELIX       424    426       {ECO:0000244|PDB:3BI1}.
FT   HELIX       429    445       {ECO:0000244|PDB:3BI1}.
FT   STRAND      446    451       {ECO:0000244|PDB:3BI1}.
FT   STRAND      455    457       {ECO:0000244|PDB:3BI1}.
FT   STRAND      459    466       {ECO:0000244|PDB:3BI1}.
FT   HELIX       468    470       {ECO:0000244|PDB:3BI1}.
FT   HELIX       471    479       {ECO:0000244|PDB:3BI1}.
FT   STRAND      480    482       {ECO:0000244|PDB:3D7H}.
FT   TURN        486    490       {ECO:0000244|PDB:2JBK}.
FT   HELIX       493    500       {ECO:0000244|PDB:3BI1}.
FT   STRAND      504    506       {ECO:0000244|PDB:3BI1}.
FT   STRAND      507    510       {ECO:0000244|PDB:4NGP}.
FT   STRAND      517    519       {ECO:0000244|PDB:3BI1}.
FT   HELIX       521    526       {ECO:0000244|PDB:3BI1}.
FT   STRAND      531    538       {ECO:0000244|PDB:3BI1}.
FT   STRAND      541    543       {ECO:0000244|PDB:3BI1}.
FT   TURN        545    547       {ECO:0000244|PDB:3D7H}.
FT   TURN        550    553       {ECO:0000244|PDB:3BI1}.
FT   HELIX       559    565       {ECO:0000244|PDB:3BI1}.
FT   HELIX       571    589       {ECO:0000244|PDB:3BI1}.
FT   HELIX       597    615       {ECO:0000244|PDB:3BI1}.
FT   HELIX       619    624       {ECO:0000244|PDB:3BI1}.
FT   HELIX       630    652       {ECO:0000244|PDB:3BI1}.
FT   HELIX       658    673       {ECO:0000244|PDB:3BI1}.
FT   STRAND      684    686       {ECO:0000244|PDB:1Z8L}.
FT   STRAND      689    695       {ECO:0000244|PDB:3BI1}.
FT   STRAND      698    705       {ECO:0000244|PDB:3BI1}.
FT   HELIX       706    712       {ECO:0000244|PDB:3BI1}.
FT   HELIX       715    717       {ECO:0000244|PDB:3BI1}.
FT   HELIX       721    744       {ECO:0000244|PDB:3BI1}.
SQ   SEQUENCE   750 AA;  84331 MW;  AD8C0A7DBF47901A CRC64;
     MWNLLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLFG WFIKSSNEAT NITPKHNMKA
     FLDELKAENI KKFLYNFTQI PHLAGTEQNF QLAKQIQSQW KEFGLDSVEL AHYDVLLSYP
     NKTHPNYISI INEDGNEIFN TSLFEPPPPG YENVSDIVPP FSAFSPQGMP EGDLVYVNYA
     RTEDFFKLER DMKINCSGKI VIARYGKVFR GNKVKNAQLA GAKGVILYSD PADYFAPGVK
     SYPDGWNLPG GGVQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY
     DAQKLLEKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN EVTRIYNVIG
     TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAAVVHEIVR SFGTLKKEGW RPRRTILFAS
     WDAEEFGLLG STEWAEENSR LLQERGVAYI NADSSIEGNY TLRVDCTPLM YSLVHNLTKE
     LKSPDEGFEG KSLYESWTKK SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN
     WETNKFSGYP LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVFELANS IVLPFDCRDY
     AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSAVKNFT EIASKFSERL QDFDKSNPIV
     LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSHNKY AGESFPGIYD ALFDIESKVD
     PSKAWGEVKR QIYVAAFTVQ AAAETLSEVA
//
